ABBOTT PARK, Ill., Jan. 23, 2019 /PRNewswire/ — Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2018, and issued financial outlook for 2019. Full-year 2018 worldwide sales of $30.6 billion increased 11.6 percent on a reported basis and 7.3 percent on an organic* basis. Reported diluted EPS from […]
Tag: Abbott
Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
ABBOTT PARK, Ill., Jan. 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib). The approval further expands Abbott’s portfolio of cardiac ablation tools that integrate […]
Abbott To Acquire Cephea Valve Technologies, Inc.
ABBOTT PARK, Ill., Jan. 16, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an […]
FDA Approves World’s First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)
ABBOTT PARK, Ill., Jan. 14, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world’s first medical device that can be implanted in the tiniest babies (weighing as little as two pounds) using a minimally invasive procedure to treat patent ductus arteriosus, or […]
ABBOTT’S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not […]
New Study Shows Abbott’s Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ — For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient’s side in as […]
Abbott Names Robert B. Ford President, Chief Operating Officer
ABBOTT PARK, Ill., Oct. 15, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott’s largest business. In addition to his current responsibilities for Medical Devices, Mr. Ford, 45, […]
ONE-YEAR RESULTS FROM REAL-WORLD STUDY SHOWED ABBOTT’S PORTICO™ TRANSCATHETER AORTIC VALVE SAFELY AND SUCCESSFULLY REDUCED SEVERE AORTIC STENOSIS
SAN DIEGO, Sept. 25, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced one-year results from a real-world, international, multicenter, 941-patient study of the company’s Portico™ transcatheter aortic valve replacement (TAVR) system in patients with symptomatic, severe aortic stenosis – a life-threatening narrowing of the heart’s aortic valve. At one year, implantation with […]
Landmark Study Shows Treatment with Abbott’s MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation
SAN DIEGO, Sept. 23, 2018 /PRNewswire/ — Abbott (NYSE :ABT ) today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or a leaky heart valve, as a result of advanced heart failure. The landmark […]
Abbott Begins U.S. Pivotal Trial for the Tendyne Mitral Valve Replacement System to Treat Patients with Heart Valve Disease
ABBOTT PARK, Ill., July 26, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of mitral regurgitation. The trial will evaluate the safety and efficacy of the treatment in patients suffering from mitral […]
Recent
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions
Late-Breaking Clinical Trial Results Announced at VIVA 2025
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
Popular
- No commented posts yet